TY - JOUR
T1 - Difficulties in emotional regulation and substance use disorders
T2 - A controlled family study of bipolar adolescents
AU - Wilens, Timothy E.
AU - Martelon, Mary Kate
AU - Anderson, Jesse P.
AU - Shelley-Abrahamson, Rachel
AU - Biederman, Joseph
N1 - Funding Information:
Dr. Timothy Wilens in the past 3 years has received research support from NIH (NIDA) and Shire; and has been a consultant for Euthymics, Lilly and Shire. Dr. Wilens has a published book with Guilford Press: Straight Talk About Psychiatric Medications for Kids. Dr. Joseph Biederman is currently receiving research support from the following sources: Elminda, Janssen, McNeil, and Shire. In 2011, Dr. Joseph Biederman gave a single unpaid talk for Juste Pharmaceutical Spain, received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course, and received an honorarium for presenting at an international scientific conference on ADHD. He also received an honorarium from Cambridge University Press for a chapter publication. Dr. Biederman received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Eli Lilly, Shire and AstraZeneca; these royalties are paid to the Department of Psychiatry at MGH. In 2010, Dr. Joseph Biederman received a speaker's fee from a single talk given at Fundación Dr. Manuel Camelo A.C. in Monterrey Mexico. Dr. Biederman provided single consultations for Shionogi Pharma Inc. and Cipher Pharmaceuticals Inc.; the honoraria for these consultations were paid to the Department of Psychiatry at the MGH. Dr. Biederman received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In 2009, Dr. Joseph Biederman received a speaker's fee from the following sources: Fundacion Areces (Spain), Medice Pharmaceuticals (Germany) and the Spanish Child Psychiatry Association. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, Alza, AstraZeneca, Boston University, Bristol Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Hastings Center, Janssen, McNeil, Merck, MMC Pediatric, NARSAD, NIDA, New River, NICHD, NIMH, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, Phase V Communications, Physicians Academy, The Prechter Foundation, Quantia Communications, Reed Exhibitions, Shire, The Stanley Foundation, UCB Pharma Inc., Veritas, and Wyeth. All other authors (MaryKate Martelon, Jesse Anderson, and Rachel Shelley-Abrahamson) declare that they have no conflicts of interest.
Funding Information:
Funding for this study was provided by NIH R01 DA12945 (T.W.) and K24 DA016264 (T.W.); the NIH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Background: Self-regulatory mechanisms appear etiologically operant in the context of both substance use disorders (SUD) and bipolar disorder (BD), however, little is known about the role of deficits in emotional self-regulation (DESR) as it relates to SUD in context to mood dysregulation. To this end, we examined to what extent DESR was associated with SUD in a high-risk sample of adolescents with and without BD. Methods: 203 families were assessed with a structured psychiatric interview. Using the Child Behavior Checklist (CBCL), a subject was considered to have DESR when he or she had an average elevation of 1 standard deviation (SD) above the norm on 3 clinical scale T scores (attention, aggression, and anxiety/depression; scores: 60 × 3 ≥ 180). Results: Among probands and siblings with CBCL data (N= 303), subjects with DESR were more likely to have any SUD, alcohol use disorder, drug use disorder, and cigarette smoking compared to subjects with scores <180 (all p values <0.001), even when correcting for BD. We found no significant differences in the risk of any SUD and cigarette smoking between those with 1SD and 2SD above the mean (all p values >0.05). Subjects with cigarette smoking and SUD had more DESR compared to those without these disorders. Conclusions: Adolescents with DESR are more likely to smoke cigarettes and have SUD. More work is needed to explore DESR in longitudinal samples.
AB - Background: Self-regulatory mechanisms appear etiologically operant in the context of both substance use disorders (SUD) and bipolar disorder (BD), however, little is known about the role of deficits in emotional self-regulation (DESR) as it relates to SUD in context to mood dysregulation. To this end, we examined to what extent DESR was associated with SUD in a high-risk sample of adolescents with and without BD. Methods: 203 families were assessed with a structured psychiatric interview. Using the Child Behavior Checklist (CBCL), a subject was considered to have DESR when he or she had an average elevation of 1 standard deviation (SD) above the norm on 3 clinical scale T scores (attention, aggression, and anxiety/depression; scores: 60 × 3 ≥ 180). Results: Among probands and siblings with CBCL data (N= 303), subjects with DESR were more likely to have any SUD, alcohol use disorder, drug use disorder, and cigarette smoking compared to subjects with scores <180 (all p values <0.001), even when correcting for BD. We found no significant differences in the risk of any SUD and cigarette smoking between those with 1SD and 2SD above the mean (all p values >0.05). Subjects with cigarette smoking and SUD had more DESR compared to those without these disorders. Conclusions: Adolescents with DESR are more likely to smoke cigarettes and have SUD. More work is needed to explore DESR in longitudinal samples.
KW - Adolescents
KW - BD
KW - Bipolar disorder
KW - CBCL
KW - Child Behavior Checklist
KW - Cigarettes
KW - DESR
KW - Deficits in emotional self-regulation
KW - Dysregulation
KW - Juvenile bipolar disorder
KW - Substance use disorders
KW - Tobacco
UR - http://www.scopus.com/inward/record.url?scp=84881662647&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2013.01.015
DO - 10.1016/j.drugalcdep.2013.01.015
M3 - Article
C2 - 23422834
AN - SCOPUS:84881662647
SN - 0376-8716
VL - 132
SP - 114
EP - 121
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
IS - 1-2
ER -